{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:59:40Z","timestamp":1793656780395,"version":"4.5.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105905","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:10:32Z","timestamp":1763658632000},"page":"105905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors"],"prefix":"10.1016","volume":"10","author":[{"given":"A.","family":"Minchom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lind\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2523-137X","authenticated-orcid":false,"given":"D.G.","family":"Knapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-1454","authenticated-orcid":false,"given":"F.I.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5137-0384","authenticated-orcid":false,"given":"J.","family":"Pinkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3482-2406","authenticated-orcid":false,"given":"F.","family":"Bladt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8546-5537","authenticated-orcid":false,"given":"H.","family":"Hennekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.esmoop.2025.105905_bib1","doi-asserted-by":"crossref","first-page":"28164","DOI":"10.18632\/oncotarget.4461","article-title":"Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types","volume":"6","author":"Lamberts","year":"2015","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105905_bib2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105905_bib3","first-page":"437","article-title":"Targeted alpha therapy with thorium-227","volume":"35","author":"Frantellizzi","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105905_bib4","first-page":"497","article-title":"Advances in precision oncology: targeted thorium-227 conjugates as a new modality in targeted alpha therapy","volume":"35","author":"Hagemann","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.esmoop.2025.105905_bib5","article-title":"Targeted thorium-227 conjugates as treatment options in oncology","volume":"9","author":"Karlsson","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105905_bib6","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1158\/1078-0432.CCR-18-3476","article-title":"Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers","volume":"25","author":"Hagemann","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105905_bib7","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"75","key":"10.1016\/j.esmoop.2025.105905_bib8","doi-asserted-by":"crossref","first-page":"34103","DOI":"10.18632\/oncotarget.26135","article-title":"Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models","volume":"9","author":"Quanz","year":"2018","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105905_bib9","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105905_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","article-title":"The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region","volume":"74","author":"van Schie","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105905_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","article-title":"Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation","volume":"72","author":"van Schouwenburg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.esmoop.2025.105905_bib12","article-title":"Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland","volume":"25","author":"Vizcaya","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105905_bib13","first-page":"1715","article-title":"89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin-targeted 227Th-conjugate therapy in mice","volume":"63","author":"Broer","year":"2022","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105905_bib14","first-page":"316","article-title":"In vitro and in vivo comparison of 3,2-HOPO versus deferoxamine-based chelation of zirconium-89 to the antimesothelin antibody anetumab","volume":"36","author":"Roy","year":"2021","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105905_bib15","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/1078-0432.CCR-15-1272","article-title":"ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody\u2013drug conjugate treatment","volume":"22","author":"Lamberts","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105905_bib16","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105905_bib17","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","article-title":"Hematologic toxicity profile and efficacy of [(225)Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer","volume":"49","author":"Lawal","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105905_bib18","first-page":"672","article-title":"(227)Th-labeled anti-CD22 antibody (BAY 1862864) in relapsed\/refractory CD22-positive non-Hodgkin lymphoma: a first-in-human, phase I study","volume":"36","author":"Lind\u00e9n","year":"2021","journal-title":"Cancer Biother Radiopharm"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105905_bib19","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2967\/jnumed.121.263310","article-title":"(223)Ra induces transient functional bone marrow toxicity","volume":"63","author":"Parlani","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.esmoop.2025.105905_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.731","article-title":"1198P Phase Ib portion of the ACTION-1 phase Ib\/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: safety and efficacy findings","volume":"34","author":"Strosberg","year":"2023","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105905_bib21","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105905_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12149-016-1093-8","article-title":"Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases","volume":"30","author":"Yoshida","year":"2016","journal-title":"Ann Nucl Med"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105905_bib23","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00259-013-2427-6","article-title":"Phase I pharmacokinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichloride in men with castration-resistant metastatic prostate cancer","volume":"40","author":"Carrasquillo","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105905_bib24","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2967\/jnumed.115.157123","article-title":"A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases","volume":"56","author":"Chittenden","year":"2015","journal-title":"J Nucl Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:01:53Z","timestamp":1773813713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017740"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105905","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105905"}}